Understanding the function of ABCA7 in Alzheimer's disease.
Wollongong, Australia. In Biochem Soc Trans, 01 Nov 2015
Our initial studies showed that transient overexpression of ABCA7 in Chinese hamster ovary cells stably expressing human amyloid precursor protein (APP) resulted in an approximate 50% inhibition in the production of the AD-related amyloid-β (Aβ) peptide as compared with mock-transfected cells.
APP intracellular domain-WAVE1 pathway reduces amyloid-β production.
New York City, United States. In Nat Med, Sep 2015
Here we report that the amyloid precursor protein (APP) intracellular domain (AICD) downregulates Wiskott-Aldrich syndrome protein (WASP)-family verprolin homologous protein 1 (WAVE1 or WASF1) as part of a negative feedback mechanism to limit Aβ production.
Inhibition of amyloid-β plaque formation by α-synuclein.
München, Germany. In Nat Med, Jul 2015
Here we performed intracerebral injections of α-syn-containing preparations into amyloid precursor protein (APP) transgenic mice (expressing APP695(KM670/671NL) and PSEN1(L166P) under the control of the neuron-specific Thy-1 promoter; referred to here as 'APPPS1').
Structural origin of polymorphism of Alzheimer's amyloid β-fibrils.
Los Angeles, United States. In Biochem J, 2012
propose that the strength of inter-strand side-chain interactions determines the degree of beta-sheet twist, which then leads to the different association patterns between different cross beta-units and thus distinct fibril morphologies
Down's syndrome and Alzheimer's disease: towards secondary prevention.
More papers using
Trenton, United States. In Nat Rev Drug Discov, 2012
[review] Based on the apparent common pathogenic role of amyloid precursor protein in both Down's syndrome and Alzheimer's disease (AD), the idea that the dementia associated with Down's syndrome is in fact AD is supported on many levels.
Immune effects of cocoa procyanidin oligomers on peripheral blood mononuclear cells
In Genes and immunity, 2006
... For transcript stabilization studies, cells in X-VIVO were treated with APP (Apple PolyR, Littleton, CO, USA) at 54μg/mL, recombinant human TNFα (PeproTech, Rocky Hill, NJ, USA) at 50ng/mL, recombinant bovine TNFα (Thermo Scientific, Waltham, MA), PC1 (Phytolab, ...